Currently available synthetic grafts have contributed to improved outcomes in cardiovascular surgery. However, the implementation of these graft materials at small diameters have demonstrated poor patency, inhibiting their use for coronary artery bypass surgery in adults. Additionally, when applied to a pediatric patient population, they are handicapped by their lack of growth ability. Tissue engineered alternatives could possibly address these limitations by producing biocompatible implants with the ability to repair, remodel, grow, and regenerate. A tissue engineered vascular graft (TEVG) generally consists of a scaffold, seeded cells, and the appropriate environmental cues (i.e., growth factors, physical stimulation) to induce tissue formation. This review critically appraises current state-of-the-art techniques for vascular graft production. We additionally examine current graft shortcomings and future prospects, as they relate to cardiovascular surgery, from two major clinical trials.
CITATION STYLE
Matsuzaki, Y., John, K., Shoji, T., & Shinoka, T. (2019, April 1). The evolution of tissue engineered vascular graft technologies: From preclinical trials to advancing patient care. Applied Sciences (Switzerland). MDPI AG. https://doi.org/10.3390/app9071274
Mendeley helps you to discover research relevant for your work.